STX-478 is a Potentially Best-in-class Mutantselective PI3Ka Inhibitor That Demonstrates Robust Efficacy in ER Plus Breast Cancer Models As Monotherapy and in Combination with Standard of Care Agents
CANCER RESEARCH（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined